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Cloning and nucleeotide sequence analysis of the human cakitanin mRNA From the BEN hmg carcinoma 
cell line, a ceB fine known to secrete high-Mr forms of cakitonin, showed no difference in the coding region 
at the nucleotide level compared with calcitonin mRNA isolated from medullary thyroid carcinoma which 
secretes calcitonin monomer. Therefore, the secretion of high-M, forms of calcitonin reflects the absence 
or limited activity of proteolytic processing enzymes within the secretory pathway of this cell line. in ail 
other respects, as judged by RNA blatting and S, mapping, calcitonln/a-CGRP expression was identical 
to that found in medullary thyroid carcinoma, including the differential use of an alternative splice donor 
site within intron 1. The BEN cell line also produces low levels of a-CGRP mRNA and secretes CGRP 
antigenic determinants. Analysis of plasma CGRP levels in 12 patients with anaplastic lung carcinoma 
showed elevated levels in 11 of these, suggesting that CGRP may be an important diagnostic marker for 
this disease. 
Lusg carcinoma ~edu~~~ry thy&d c~c~noma ~roteo~ytic pr~e~~~g RNA ~p~ic~~g 
Calcitonin gem-related peptic &topic synt~~~~ 
1. INTRODUCTION 
Studies on the expression of the rat and human 
calcitonin gene have demonstrated the generation, 
via post-transcriptional processing events, of two 
distinct mRNA species encoding polyproteins 
which contain either calcitonin or the a-calcitonin 
gene-related peptide (m-CGRP) [1,2],. A second 
gene encoding human @-CGRP has also been 
described 12,31. Calcitonin is normally synthesized 
by the C-cells of the thyroid (see [4]) and CGRF is 
co-produced by the same cells [S]. Discrete CGRP- 
producing cells are also found in the thyroid [5] 
and widely distributed in the central and peripheral 
nervous system [5]. Calcitonin and CGRP are syn- 
thesized as precursor polyproteins, which are 
cleaved and then amidated prior to secretion [7,8]. 
Cal& onin biosynthesis also occurs ectopically in 
no~~thyroidal tumours including lung f9,10] and 
+ To whom corr~ponden~ should be addressed 
phaeochromoc~omas [1 I]. Many such tumours 
secrete immunoreactive calcitonin of high Mr and 
little of the monomer (Mr 3500) [12,13]. We have 
previously described the ectopic expression of the 
calcitoninla-CGRP gene in two small (oat) cell 
lung carcinoma cell lines, as judged by SI nuclease 
mapping and cDNA hybridisation analysis [Z], 
Here we examine by cDNA cloning, RNA 
hybridisation analysis, St mapping and radioim- 
munoassa~, the expression of the human calcitonin 
a-CGRP gene in a human large-cell bronchial car- 
cinoma cell line (BEN), a cell line known on the 
basis of gel filtration analysis and immunological 
evidence to synthesise high-Mr forms of biological- 
ly inactive calcitonin [13-151. Our results 
demonstrate that: the high-M, variant of calcitonin 
reported by others reflects the absence, or limited 
activity only, of prohormone processing enzymes 
within the secretory pathway of these cells; the 
biosynthesis of calcitonin rnRNA in lung car- 
cinoma cell lines and medullary thyroid carcinoma 
cm24x3RP mRNk; and CGRP ~~tj~~~ic deter- 
min&M.a re present in BEN cell %cretions, and in 
phmra frron patients with lung catclsoma. In view 
of these observations, it is likely that the numerous 
reports in the literature describing the presence of 
high-&& variants of small peptide hormones, either 
circulating in piasma from patients with endocrine 
t~~~~~s~ or in secretions from ~t~~~~s~~~ c&I 
firaes, asr: a refketion of abemt ~~s~~t~~s~~~~~~~~ 
~~~~~~~ & tk pm3mBr ~~~~r~~~~~~s~ 
Adtw~ine 5 ’ -[y-32P]triphosphate (3000 Ci/ 
mmol) and deoxycytidine 5’-[~-“2Pjtn’iphosph~te 
(410 ClSmmol) were obtained from ‘New England 
Nucleulr or Amersham International, 
TstJ RNA was isolated from confluent BEN 
cells by the method of Hall et al, [l 6;l and the 
~oly~A~~~o~taining RNA fraction obtstised by af- 
finity ~b~omatography using ~1~~~~~T~ cellulose 
fl% 
~~Iy~A~-con~~g RSA %%s ~~~~ under 
d~~~~~~~g conditions by el~~~~~~~~s~$ through 
1 i 1 @To (w/v) agarose gels and blotted auto Riodyne 
membranes as described by Taylor ct al. 1181. 
Nick-translation of sequence-specific cDNA 
hybridisafion probes using [cy-3aP]dCTP was as 
described by Edbrooke et al. [2], 
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Double&randed cDNA was synthesised from 
total poly(A)-containing RNA essentially BS 
described by Qubler and Hoffman [20] except that 
residual hairpin loops were removed by St 
nuclease, The double-stranded cDNA was then 
blur& ended using T* DNA polymerase:, ~~t~r~~ 
EcoRf sites were rn~th~lat~ and &X%X hnkers 
ridded and &aved. %ese were &en chro- 
~~~~~~~ on U&rogeI AcA M (I X 0.5 cm] in 
the presence of EcoRI-cnt, phos~~ata~~ &@I 
DNA, and Eha nucleic acid recovered by &ban01 
precipitation from the void volume, ligated, 
packaged, and plated onto E. coli YlOS& cells (see 
[21-231) Recombinant phage containing cal- 
citonin cDNA sequences was identified using aa& 
labelled ~i~~~t~~~sl~ted calcitonin cDNA @4], 
plaque purifie& and the inserted cafcitonin cDlQA 
then r~lo~~d dire&y into MI3 vectors ~~~~I~~ 
mptl, mp18, mpl9) for DNA sequence ~~~~~~s 
@5] aud -St .~a~~i~g~ 
Radioirnmunoassay using rabbit avvlisera raised 
against Tyr-CGRPzs-37 amide conjugated to 
ovalbumim was essentially as described for the 
calcitonin ;ussay [26] except that 12SI-labelXed Tyr- 
CGRP~~l~~6&nide tracer was qu~tit~t~~~~~ 
recovered by ~~~c~pitation using goat a~ti-~~bbi~ 
serum (IQ ~1) titer the addition of f PI ~r~-~m~~~~ 
rabbit scrap gorier to each 400$X& assay ]2& 
We have described elsewhere the charactarisa- 
tion and expression of the human calcitaain/w 
CGRP gene in medullary thyroid carcinoma and 
two small-call carcinoma cell lines [2,27,28]+ As an 
extension of t&se results we have examined the ec- 
roplc ~~~~s$l~~ of the calcitoni~~~-~G~~ @ma in 
an ~~a~~sb~ b~rna~ Itmg ~~~orn~ c&l firre 
@SN-), ~~~v~~~sIy shown to secrete a -& form 
of b~o~~~~~~y inactive human c~clt~~~~ _EI 3- IS]_ 
Analysis of total BEN cell poly(A~c~~~a~~i~g 
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RNA by RNA blotting using previously well 
characterised calcitonin and CGRP hybridisation 
probes [2] demonstrated ffig.1, tracks i&i) an 
abundance of calcitonin mRNA (0.9-1.0 kb) and 
very much lower levels of CGRP mRNA. A 
number of higher M, RNA species were also iden- 
tified. Using a CGRP cDNA probe, 4.2 and 3.4 kb 
species of equivalent intensity of the CGRP 
mRNA, and a less intensely hybridising band of 
2.6 kb were clearly identifiable. A larger 5.2 kb 
species was also just discernible. Using the 
i ii Ili 
Fig. 1. Expression of the C~citonin~~~C~RP gene in the 
BEN ceil line. Schematic representation of the 
c~citonin/~-CGR~ gene (comprising 6 exons and 5 
introns) illustrates the transcribed regions of the gene 
from which the cDNA probes were derived (see [30]). 
BEN ceil line poly(A)-containing RNA (7pg) was 
separated in duplicate by agarose gel electrophoresis and 
blotted onto Biodyne filters. One filter was probed with 
a CORP-specific probe (track ii; phTB58 fSg/II/PstI, see 
[2]). After autoradiography, the filter was washed and 
reprobed with a cahzitonin-specific probe (track i; phTB3 
.&fiI/Psti, see [Z]) and autor~io~~~~~~ again. The 
other filter was probed with an intros-s~i~c probe 
(track iii; phTB58 ~g~I/Bg~I, see f2l). Specific 
activities of probes were I-2 x 107 cpm/$g and all 
autoradiographs were for 16 h. RNA sizes are in kb. 
calcitonin cDNA probe, the 4.2 and 3.4 kb species 
were again identified, though at comp~atively ow 
levels when compared with the mature calcitonin 
mRNA, whilst a 2.2 kb band which did not 
hybridise to a CGRP cDNA probe and has 
previously been shown to be an intermediate in the 
synthesis of calcitonin mRNA from a common 
precursor (see [2]) was also evident. In this experi- 
ment the 2.6 kb band could not be distinguished 
over background using the calcitonin cDNA 
probe, though we have identified its presence in 
other experiments, using total poly{A~~ont~ning 
RNA from BEN, DMS 53 and DMS 153 cell lines 
f32] and medullary thyroid carcinoma (see [2]; Ed- 
brooke and Craig, unpublished~. Analysis of BEN 
cell line total poly(A)~ont~ning RNA on a 
separate filter using a probe specific to the intron 
separating the calcitonin and CGRP exons (fig.1, 
track iii) as expected showed no hybridisation to 
the processed mRNA species, but in common with 
previous data [2] hybridised to the 4-2, 3.4 and 
2.6 kb RNA species, but not the 2.2 kb species, 
Con~rmation that processed wCGRP as opposed 
to &CGRP transcripts (see f2]) were expressed in
the BEN cell fine was obtained by SI mapping 
using a 32P-labelled ~~o~/~~oI cDNA fragment 
(309 bp} obtained from a cloned parti~Iy pro- 
cessed caI~ito~n/~-CGRP cDNA transcript, 
described elsewhere (see fig.1; also [2]). Thus, 
comparison of total poly(A)-containing RNA from 
BEN cells and from a medullary thyroid carcinoma 
known to express c~-CGRP mRNA (see [2]; also 
fig.2) demonstrated the protection of the expected 
244 bp fragment after Si analysis, thereby con- 
firming the presence of processed CFCGRP 
transcripts. Analysis of medium exposed to BEN 
cells for 4 days using a CGRP radioimmun~say 
f2] demonstrated the presence of CGRP antigenic 
determinants and so confirmed that the low levels 
of 1.1 kb CGRP mRNA observed indeed 
represented translatable mRNA. ParalleI analysis 
of plasma from 12 anaplastic lung-carcinoma pa- 
tients compared with normal control plasma also 
showed significant levels of CGRP antigenic deter- 
minants in all but one of the samples examined 
(fig.3 and table 1). Normal plasma CGRP levels 
have been reported in the range 20-50 pmol/l[41 f. 
Although our present assay is not sensitive in this 
range, our data suggest hat CGRP levels can be 
elevated as much as 2Wfold in lung carcinoma. 
73 
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Axt~houg~ the expression of tha ~~citonin~~- 
CCRP gene by the BEN ceh line is identical to that 
of the gene in rn~u~~~y &y&d carcinoma as 
judged by RNA bgottkg and 5% ~~~pi~~, such an 
approach wilt not detect single base su#stitut~o~ 
witbin the genome, which may lead to amino acid 
~~~~tituti~n and so abnormal protein processing, 
Such lesions, the potential basis of the expression 
of large calcitonin, can only be identified by cDNA 
cloning and nucleotide sequence analysis. We have 
coustructed a representative cRNA Iibrary (2 x 10” 
re~~~b~~ants) in the expression vector Agtl 1 using 
total BEN ceil po~y~A~-contai~~~~ RNA. Pre- 
timInary screening, using exiding “‘P-labe&ed 
c~~ei~~~~ and~~~~-~~ec~~~c cDNA ~~~d~~~~~ 
probes, showed that fi.1 3% of the r~ornb~~ts 
cum&red c&&min cDNA, whifst O.Dl% con- 
tamed CARP cDNA sequences. Six recombinants 
showing positive hybridisation to calcitonhr cDNA 
were pla~ua purified and the size of the inserted 
cDNA analysed after restriction with .&oRZ. The 
largest cDNA insert ~h~EN-~~~~ was then 
restric&x! w&h &&I or 5)&I, recloned f&o Mi3 
vectors arrd the nucteotide sequence determined on 
both strands and across ah internal restriction sites 
used for doning. This revealed ffigd) that the 
cloned cDNA fragment (723 nucleot~d~s~ com- 
prised the entire coding sequence of the human 
calcitonin mRNA, and most of the J’- and 
5 ’ -untrau&ted regions. The coding region was in 
complete ~~~~~rnent with previous reports of the 
nucleotidct sequence and encodes a p~~~~~~t~~i~ 
po&protcrin {Mr 15 45 f ) with an amino acid se- 
quence idt?rrticaI to that derived from simiiar 
ana&& of clones isokted from human m~~~Iar~ 
thyroid carcinoma eDNA Libraries {29,3#]. Thus, 
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Table 1 
Identification of elevated plasma CGRP in anaplastic 
lung carcinoma 
Plasma sample 
Lung carcinoma 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
4 day BEN secretion 
MCT 
Normal plasma 
CGRP (nmol/l) 
1.3 
3.4 
5.0 
11.0 
7.0 
12.0 
2.2 
5.0 
n.d. 
5.0 
11.0 
6.2 
9.0 
26 
n.d. 
n.d. 
n.d. 
n.d., not detectable 
-84 -80 -70 
Met 9 Phe Gln B Phe Set Pro Phe Leu Ala Leu Ser Ile Leu Val Leu -- ---1-------- 
5' GGTGAGCCCCGAGATTCTGGCTCAGAGAGGTGTC ATd GC TC CAA AAG TTC TCC CCC TTC CTG GCT CTC AGC ATC TTG GTC CTG 
in a cell line which secretes high-M forms of im- 
munoreactive calcitonin, calcitonin( l-32) is 
flanked within the polyprotein by signal peptide, 
amino and carboxyl flanking sequence, and 
separated from these by basic amino acids (-2, 
- 1 and f 2, -t 3, + 4), and the glycine residues 
( + 1) necessary for amidation [3 11. The termina- 
tion codon (TAA) is also, as expected, adjacent to 
the asparagine residue (+25) of the flanking pep- 
tide PDN-21 [27]. Within the 3 ‘-untranslated 
region no differences were observed though the 
cloned cDNA sequence stops short of the 
polyadenylation site (see 1271). 
In contrast, within the 5’-untranslated region 
the sequence diverges from the previous published 
sequence at a point 10 nucleotides upstream from 
the initiating methionine, the known splice point 
between exon 1 and exon 2 of the human calcitonin 
gene (see [30]). The novel sequence present at the 
5 ‘-end of the BEN cell line calcitonin mRNA can 
also be found in the calcitonin genomic sequence 
within intron 1 (see figSA), where an alternative 
exon 1 splice donor site (GCTCAG) must occur 24 
nucleotides to the 3’-side of the previously iden- 
-60 -50 
Leu Glu Ala 9 Ser Leu His Ala Ala Pro Phe & Ser Ala Leu Glu Ser Ser Pro Ala 9 Pro Ala Thr Leu Ser Glu -_I- ------- _-----c_ -_---- 
TTG CAG GCA GGC AGC CTC CAT GCA GCA CCA TTC AGG TCT GCC CTG GAG AGC AGC CCA GCA GAC CCG GCC ACG CTC AGT GAG 
A 
-40 -30 -20 
Asp Glu Ala Arg Leu Leu Leu Ala Ala Leu Val Gln Asp Tyr Val Gln Met Lys Ala Ser Glu Leu Glu Gin Glu Gin Glu --------- 
GAC GAA GCG CGC CTC CTG CTG GCT GCA CTG GTG CAG GAG TAT GTG CAG ATG AAG GCC AGT GAG CTG GAG CAG GAG CAA GAG 
+10 +20 +25 
Leu Glu Arg ASE His & Pro His Val Ser Met Pro Gln Asn Ala Asn term -- ----------- 
TTG GAG AGA GAC CAT CGC CCT CAT GTT AGC ATG CCC CAG AAT GCC AAC TAA ACTCCTCCCTTTCCTTCCTAATTTCCCTTCTTGCATCCT 
TCTGAATGTGC 3' 
Fig.4. Complete nucleotide sequence of calcitonin polyprotein mRNA isolated from the BEN cell line and cloned into 
hBEN-JR2. Sequencing was performed on both strands, and across all restriction sites used to clone into Ml3 vectors. 
Vertical arrows indicate positions of splice junctions. Boxed sections of amino acids indicate sites for proteolytic 
processing or amidation (see text). The large triangle indicates the potential cleavage site for the signal peptide (see (291). 
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Exon? fntmn 1 fntmn1 Exon 2 
* * 
+J----. ;:: 
GC~C~CC~~gtgag~~~~g~gat~ctg~c------O.8? kb-----tcccttgcagAGAGGTGlY%% 
Met 
-------------GGTGACCCCCGAGATTCTGGCTCAG _vAGAG TGTCii?% 
353- 
i ii iii iv v 
76 
-344 
-298 
-221 
Fig.5. An alternative splice donor sequence in intron 1 of 
the calcitoninla-CGRP gene gives rise to different 
5’ -leader sequences for human calcitonin rnRNA, {A) 
Ide~t~fi~t~o~ f an alternative splice donor site in intron 
I. Human genomic DNA sequence is as described by 
Jonas et al. 130) and the 5’4eader sequence of calcitonin 
rnRNA from MCT is as described by Le Moullee et al. 
[29] and Jonas et al. [3OJ. (B) Si nuclease mapping of 
poly(A)-containing RNA from DMS 53 (i, 100 ng), BEN 
cell line (ii, 200 ng), medullary thyroid carcinoma (iii, 
100 ng) and E. co& tRNA (v, 200 ng) using a single- 
stranded DNA probe (353 nucleotides, track iv) 
generated from Ml3 (see section 2). 32P-labelled HinfI- 
restricted pBR322 DNA markers were electrophoresed in
parallel and their relative positions indicated. 
tified donor site (GCCAG), the site apparently 
favoured in medulhuy thyroid carcinoma, as 
judged by nucleotide sequence analysis of human 
calcitonin cDNA derived from this source [29,30]” 
To establish whether the alternative splice site is 
favoured, or used exclusively inthe ectopic expres- 
sion of ~alcito~in mRNA by lung carcinoma celi 
lines, as opposed to medullary thyroid carcinoma, 
we have examined by Sr mapping the relative usage 
of the alternative 5 ‘-Ieader sequence in total 
poly~A~-~ont~ning RNA isolated from BEN cells, 
medullary thyroid carcinoma, and the DMS 53 
small-cell carcinoma ceff fine, the latter derived 
from small-cell carcinoma of the lung and known 
to express the calcitonin’cr-CGRP gene [2,32]. Sr 
mapping was performed using a 353 nucleotide 
32P-labelled single-stranded DNA hybridisation 
probe representative of the 306 nucleotide 
calcitonin cDNA sequence in hBEN-JR2 to the 5 ’ 
of the Q/z1 site within the calcitonin coding se- 
quence, flanked by 47 nucleotides of Ml3 mp I1 
polyIinker and ohgonucleotide primer (see fig,SB, 
top). Thus protection of a fragment of 306 
nucleotides would reflect the use of the exon I 
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3 ‘-splice site (within the intron), whilst protection 
of a shorter fragment of 281 nucleotides would 
reflect the proportion of calcitonin mRNA using 
the exon I 5’-splice site. As can be seen (fig.SB), in 
the BEN and DMS 53 lung carcinoma cell lines, 
and in medullary thyroid carcinoma, both splice 
sites are utilised, in a ratio of approx. 8: 1 in 
favour of the 5 ’ - as opposed to the 3 ‘-site. Addi- 
tional protected fragments at 261 and 236 
nucleotides were also apparent. These are the ex- 
pected size of transcripts from exons II and III of 
the calcitonin gene [30], with and without the 
5 ‘-leader sequence cloned in hBEN-JR2. These 
reflect a similar usage of the alternative splice sites 
in the production of the wCGRP mRNA in the 
lung carcinoma cell lines and medullary thyroid 
carcinoma. 
4. DISCUSSION 
Cloning and characterisation of human 
calcitonin mRNA isolated from medullary thyroid 
carcinoma, a tumour which secretes both 
monomer calcitonin and high-Mr forms, has 
shown that, in common with most small 
biologically active peptides, human calcitonin is 
synthesised as a precursor polyprotein, subse- 
quently cleaved from the polyprotein by pro- 
teolytic enzymes within the secretory pathway of 
thyroidal C-cells [27,28]. These enzymes recognise 
basic amino acids flanking the amino- and 
carboxyl-terminal ends of the calcitonin peptide. 
The carboxyl-terminal proline ( + 32) is amidated 
(a requirement for biological activity) by an amida- 
tion enzyme which utilizes the amino group of 
glycine (+ 1) in the polyprotein as the source of an 
amide [31]. Studies on the BEN cell line have 
previously shown that these cells secrete an im- 
munoreactive calcitonin which is biologically inac- 
tive, and of predominantly high M, (iW 
7000-40000, see [ 13-151). Studies using human 
and rat calcitonin cDNA hybridisation probes have 
in addition shown the presence, by RNA blotting, 
of an abundant BEN cell calcitonin mRNA [33,34] 
which on the basis of cell-free protein synthesis 
and immunoprecipitation directs the synthesis of a 
17 kDa protein, similar to the mRNA-directed im- 
munoprecipitable calcitonin polyprotein identified 
using poly(A)-containing RNA isolated from 
human medullary thyroid carcinoma [34]. 
Our studies described above now define in 
molecular terms the basis of secretion by the BEN 
cells of high-n/l, forms of calcitonin. The transcrip- 
tion and post-transcriptional processing of the 
human calcitonin/cu-CGRP gene by the BEN cell 
line are identical in every way, as judged by RNA 
blotting and Si mapping, to calcitonin gene expres- 
sion in medullary thyroid carcinoma [2]. 
Calcitonin mRNA derived from a medullary 
thyroid carcinoma known to secrete calcitonin 
monomer [26,27] and calcitonin mRNA from the 
BEN cell line showed no differences within the 
coding region of the mRNA. Thus, the ectopic 
secretion of larger forms of immunoreactive 
calcitonin by the BEN and other lung carcinoma 
cell lines is not a reflection of abnormal mRNA 
processing or point mutations in the reading frame 
of the mRNA corresponding to the sites in the 
polyprotein required for post-translational pro- 
cessing. The inability of lung cells to secrete 
calcitonin monomer reflects inefficient proteolytic 
cleavage of the polyprotein prior to secretion. 
Studies on mRNA-directed protein synthesis using 
Xenopus oocytes would support this view, since 
proteolytic processing of proinsulin is not an 
obligatory requirement of the secretory process 
[35]. Consequently, the ectopic secretion of high- 
M, calcitonin, and in all probability high-M, forms 
of other peptides uch as ACTH secreted ectopical- 
ly by endocrine tumours (see [36]), reflects the 
absence of expression, or the limited expression of 
proteolytic processing enzymes, within the 
secretory pathway of tumour cells. The unex- 
pectedly high iK as judged by gel filtration of some 
of the large calcitonin secreted by the BEN cell line 
(Mr 40000) may reflect molecular asymmetry or 
glycosylation, both of which can lead to disparities 
in Mr estimations. Since glycosylation of the rat 
calcitonin polyprotein has been demonstrated 
[37,38], it is likely that glycosylation in addition to 
aberrant proteolytic processing may well con- 
tribute to the heterogeneous nature of large 
calcitonins secreted by the BEN cell line, other cell 
lines and tumours. 
The identification of significant levels of im- 
munoreactive CGRP in BEN cell secretions and in 
the plasma of 11 out of 12 anaplastic lung car- 
cinoma patients examined adds weight to ac- 
cumulating evidence [2] that CGRP may be a 
valuable diagnostic marker peptide for lung car- 
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cinema in addition to medullary thyroid car- 
cinoma (see f2,8]). In medullary thyroid car- 
cinoma, CGRP measurements are valuable ad- 
juncts to calcitonin measurements [2,8]. However, 
the frequency of elevated plasma CGRP in 
anaplastic lung carcinoma (11 out of the 12 
samples measured) suggests that CGRP will be an 
important diagnostic marker for this disease. 
The use of alternative splice donor sites, leading 
to different 5 ‘-leader sequences for human 
calcitonin mRNA at similar frequencies in lung 
carcinoma cell lines and medullary thyroid car- 
cinoma, has also been reported in studies on the rat 
calcitoninfcu-CGRP gene [40]. Both reflect the 
favoured use of one of two alternate Splice sites? 
which, unlike in a humans-thaiassaemi~ where the 
coding sequence is affected [39], have no obvious 
deleterious effect on gene expression. The alter- 
native use of these splice sites, which appears to be 
a phenomenon common to all calcitonin- and a- 
CGRP-producing cells, should not, however, be 
confused with other post-transcriptional process- 
ing events involving cleavage and polyadenylation. 
The latter, which determine in a tissue- or cell- 
specific manner whether caicitonin or c~-CGRP are 
the major products of the calcitonin’tu-CGRP 
gene, are modulated via a transacting factor (see 
12&J]). 
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